Literature DB >> 10768960

Characterization of conserved T- and B-cell epitopes in Plasmodium falciparum major merozoite surface protein 1.

M Parra1, G Hui, A H Johnson, J A Berzofsky, T Roberts, I A Quakyi, D W Taylor.   

Abstract

Vaccines for P. falciparum will need to contain both T- and B-cell epitopes. Conserved epitopes are the most desirable, but they are often poorly immunogenic. The major merozoite surface protein 1 (MSP-1) is currently a leading vaccine candidate antigen. In this study, six peptides from conserved or partly conserved regions of MSP-1 were evaluated for immunogenicity in B10 congenic mice. Following immunization with the peptides, murine T cells were tested for the ability to proliferate in vitro and antibody responses to MSP-1 were evaluated in vivo. The results showed that one highly conserved sequence (MSP-1#1, VTHESYQELVKKLEALEDAV; located at amino acid positions 20 to 39) and one partly conserved sequence (MSP-1#23, GLFHKEKMILNEEEITTKGA; located at positions 44 to 63) contained both T- and B-cell epitopes. Immunization of mice with these peptides resulted in T-cell proliferation and enhanced production of antibody to MSP-1 upon exposure to merozoites. MSP-1#1 stimulated T-cell responses in three of the six strains of mice evaluated, whereas MSP-1#23 was immunogenic in only one strain. Immunization with the other four peptides resulted in T-cell responses to the peptides, but none of the resulting peptide-specific T cells recognized native MSP-1. These results demonstrate that two sequences located in the N terminus of MSP-1 can induce T- and B-cell responses following immunization in a murine model. Clearly, these sequences merit further consideration for inclusion in a vaccine for malaria.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10768960      PMCID: PMC97475          DOI: 10.1128/IAI.68.5.2685-2691.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  26 in total

1.  Development of a malaria T-cell vaccine for blood stage immunity.

Authors:  I A Quakyi; D W Taylor; A H Johnson; J B Allotey; J A Berzofsky; L H Miller; M F Good
Journal:  Scand J Immunol Suppl       Date:  1992

2.  A carboxyl-terminal fragment of Plasmodium falciparum gp195 expressed by a recombinant baculovirus induces antibodies that completely inhibit parasite growth.

Authors:  S P Chang; H L Gibson; C T Lee-Ng; P J Barr; G S Hui
Journal:  J Immunol       Date:  1992-07-15       Impact factor: 5.422

3.  Influence of adjuvants on the antibody specificity to the Plasmodium falciparum major merozoite surface protein, gp195.

Authors:  G S Hui; S P Chang; H Gibson; A Hashimoto; C Hashiro; P J Barr; S Kotani
Journal:  J Immunol       Date:  1991-12-01       Impact factor: 5.422

4.  Allelic dimorphism in a surface antigen gene of the malaria parasite Plasmodium falciparum.

Authors:  K Tanabe; M Mackay; M Goman; J G Scaife
Journal:  J Mol Biol       Date:  1987-05-20       Impact factor: 5.469

5.  A recombinant 15-kilodalton carboxyl-terminal fragment of Plasmodium yoelii yoelii 17XL merozoite surface protein 1 induces a protective immune response in mice.

Authors:  T M Daly; C A Long
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

6.  Analysis of human T cell response to two Plasmodium falciparum merozoite surface antigens.

Authors:  C M Rzepczyk; R Ramasamy; D A Mutch; P C Ho; D Battistutta; K L Anderson; D Parkinson; T J Doran; M Honeyman
Journal:  Eur J Immunol       Date:  1989-10       Impact factor: 5.532

7.  Protection against malaria in Aotus monkeys immunized with a recombinant blood-stage antigen fused to a universal T-cell epitope: correlation of serum gamma interferon levels with protection.

Authors:  M A Herrera; F Rosero; S Herrera; P Caspers; D Rotmann; F Sinigaglia; U Certa
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

8.  Ability of recombinant or native proteins to protect monkeys against heterologous challenge with Plasmodium falciparum.

Authors:  H M Etlinger; P Caspers; H Matile; H J Schoenfeld; D Stueber; B Takacs
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

9.  Epitopes recognized by human T cells map within the conserved part of the GP190 of P. falciparum.

Authors:  A Crisanti; H M Müller; C Hilbich; F Sinigaglia; H Matile; M McKay; J Scaife; K Beyreuther; H Bujard
Journal:  Science       Date:  1988-06-03       Impact factor: 47.728

10.  A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies.

Authors:  M J Blackman; H G Heidrich; S Donachie; J S McBride; A A Holder
Journal:  J Exp Med       Date:  1990-07-01       Impact factor: 14.307

View more
  11 in total

1.  Immunogenicity of well-characterized synthetic Plasmodium falciparum multiple antigen peptide conjugates.

Authors:  M B Joshi; A A Gam; R A Boykins; S Kumar; J Sacci; S L Hoffman; H L Nakhasi; R T Kenney
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

2.  Changes in antigen-specific cytokine and chemokine responses to Plasmodium falciparum antigens in a highland area of Kenya after a prolonged absence of malaria exposure.

Authors:  Lyticia A Ochola; Cyrus Ayieko; Lily Kisia; Ng'wena G Magak; Estela Shabani; Collins Ouma; Chandy C John
Journal:  Infect Immun       Date:  2014-06-23       Impact factor: 3.441

3.  Diepitopic construct of functionally and epitopically complementary peptides enhances immunogenicity, reactivity with glucosyltransferase, and protection from dental caries.

Authors:  M A Taubman; C J Holmberg; D J Smith
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

4.  Repeat sequences in block 2 of Plasmodium falciparum merozoite surface protein 1 are targets of antibodies associated with protection from malaria.

Authors:  Spencer D Polley; Kevin K A Tetteh; David R Cavanagh; Richard J Pearce; Jennifer M Lloyd; Kalifa A Bojang; Daniel M N Okenu; Brian M Greenwood; Jana S McBride; David J Conway
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

5.  Comparative testing of six antigen-based malaria vaccine candidates directed toward merozoite-stage Plasmodium falciparum.

Authors:  David E Arnot; David R Cavanagh; Edmond J Remarque; Alison M Creasey; Mercy P K Sowa; William D Morgan; Anthony A Holder; Shirley Longacre; Alan W Thomas
Journal:  Clin Vaccine Immunol       Date:  2008-06-11

6.  Plasmodium vivax promiscuous T-helper epitopes defined and evaluated as linear peptide chimera immunogens.

Authors:  Ivette Caro-Aguilar; Alexandra Rodríguez; J Mauricio Calvo-Calle; Fanny Guzmán; Patricia De la Vega; Manuel Elkin Patarroyo; Mary R Galinski; Alberto Moreno
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

7.  A polyvalent hybrid protein elicits antibodies against the diverse allelic types of block 2 in Plasmodium falciparum merozoite surface protein 1.

Authors:  Kevin K A Tetteh; David J Conway
Journal:  Vaccine       Date:  2011-08-04       Impact factor: 3.641

8.  A malaria vaccine based on the polymorphic block 2 region of MSP-1 that elicits a broad serotype-spanning immune response.

Authors:  Graeme J M Cowan; Alison M Creasey; Kelwalin Dhanasarnsombut; Alan W Thomas; Edmond J Remarque; David R Cavanagh
Journal:  PLoS One       Date:  2011-10-26       Impact factor: 3.240

9.  A novel malaria vaccine candidate antigen expressed in Tetrahymena thermophila.

Authors:  Graeme J M Cowan; Ulrike Bockau; Janna Eleni-Muus; Ingo Aldag; Kay Samuel; Alison M Creasey; Marcus W W Hartmann; David R Cavanagh
Journal:  PLoS One       Date:  2014-01-29       Impact factor: 3.240

10.  Interferon-γ responses to Plasmodium falciparum vaccine candidate antigens decrease in the absence of malaria transmission.

Authors:  Cyrus Ayieko; Bilha S Ogola; Lyticia Ochola; Gideon A M Ngwena; George Ayodo; James S Hodges; Gregory S Noland; Chandy C John
Journal:  PeerJ       Date:  2017-01-10       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.